We are here to extend our lives by THINKING DIFFERENT

Showing posts with label NIH. Show all posts
Showing posts with label NIH. Show all posts

Friday, September 3, 2010

NIH Awards $1.2 Million To Study Protein Misfolding Diseases

NIH Awards $1.2 Million To Study Protein Misfolding Diseases




Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis.

EUREKA stands for Exceptional, Unconventional Research Enabling Knowledge Acceleration. The program was created by NIH's National Institute for General Medical Sciences to support scientists who are testing new ideas in unusual ways or tackling major methodological or technical challenges. Janna Wehrle, who manages this and other protein folding grants at NIH, says, "This project represents an exceptionally bold effort to determine how proteins fold not in a test tube but in real cells. By examining how proteins take shape in the crowded and dynamic environment where it actually occurs, this work may lead to a better understanding of how the folding process goes awry in diseases like cystic fibrosis and some forms of liver cirrhosis."

Anne Gershenson and her biochemistry and molecular biology colleagues Daniel Hebert and Lila Gierasch begin pilot studies this month using new techniques they adapted to observe how individual secretory proteins fold, not only in real cells but in real time. For this work, they will also use a powerful new super-resolution fluorescence microscope built by UMass Amherst physicist Jennifer Ross and her students. It provides a clear view of individual molecules with far more precision than was possible using traditional light microscopy.

Members of this UMass Amherst research group have been pioneers in studying proteins in situ, or in place, rather than in test tubes. Up to now, much valuable protein-folding research has used whole purified proteins that are forced by heating or other treatment to unfold in a test tube. Scientists then study their refolding into the three-dimensional shapes necessary to carry out the cell's tasks. But as Gershenson and Gierasch pointed out in an influential 2009 article in Nature Chemical Biology, "we have arrived at the post-reductionist era of biochemistry" when it is no longer enough to study isolated parts of complex networks. Rather, they say scientists must now examine proteins in their native, complicated and highly concentrated environments to truly understand the way they work.

The cell's endoplasmic reticulum is a protein-folding factory, churning out hundreds of secretory proteins to be exported from cells, as well as membrane proteins that reside on the cell surface, Gershenson explains. This factory comes complete with a large number of proteins responsible for quality control. They assist in folding and determine whether and when a protein should be exported to take up its required position. How proteins fold as they are synthesized and how quality control mechanisms affect protein folding are the focus of Gershenson and colleagues' investigation.

The UMass Amherst researchers use a technique called fluorescence resonance energy transfer, or FRET, for light-marking proteins and monitoring their folding. In it, two differently-colored fluorescent dyes that are sensitive to each other, a donor and an acceptor, are introduced into the protein chain as it is made. When these are farther apart in a not-yet-folded protein, the donor emits greener fluorescence. As the protein folds and the two dyes get closer together on the three-dimensional structure, their proximity results in emission of a redder fluorescence. Spectroscopically analyzing the fluorescence allows investigators to precisely track donor-to-acceptor distance changes.

Further, by introducing the FRET donor and acceptor molecules at slightly different parts of the protein chains in each of hundreds of experiments, Gershenson and colleagues will be able to map protein changes associated with folding in situ, in real time.

"Once we get the system operating with good fluorescence and we become adept at incorporating the FRET dyes, our method should prove useful to other researchers for studying a wide variety of other proteins which are involved in many other disease processes," she says. "That's the big promise of this approach, and the challenge."

Over the three years of the program, NIH has awarded 56 grants totaling $67.4 million to support these highly innovative research projects which promise big scientific payoffs. Awards announced today total $25.2 million to 21 institutions.

Source: University of Massachusetts Amherst

Friday, October 30, 2009

DiscoveryBioMed Awarded $300,000 NIH Grant for Cystic Fibrosis Drug Research and Development

DiscoveryBioMed Awarded $300,000 NIH Grant for Cystic Fibrosis Drug Research and Development

Wed Oct 28, 2009 11:23am EDT
Phase 1 Small Business Innovation Research (SBIR) Grant to Fund Research Performed by On-Going Collaboration between DiscoveryBioMed and The Gregory Fleming James Cystic Fibrosis Research Center at the University of Alabama at Birmingham (UAB)

BIRMINGHAM, Ala.--(Business Wire)-- DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

"SBIR funding is an essential part of DiscoveryBioMed`s ability to provide our academic clients with cost-effective access to our world-class drug discovery engine," said Dr. Erik Schwiebert, Chief Executive Officer of DiscoveryBioMed. "By screening our test drugs on DBM`s proprietary disease-relevant human cell backgrounds, our clients are able to facilitate their basic research, bringing new therapies closer to patients.

The SBIR grant announced today is an example of this strategy in action." Dr. Schwiebert continued, "We are particularly pleased that the NIH has chosen to provide funding for this important drug discovery program and we are proud to be partnered with UAB`s Gregory Fleming James Cystic Fibrosis Research Center in the pursuit of new clinical treatments for Cystic Fibrosis."

To date, DiscoveryBioMed, along with partners, James Collawn, Ph.D. and Zsuzsa Bebok, M.D., have screened approximately 25,000 compounds as part of this program. As a result of the SBIR award announced today, the team will be able to screen 50,000-70,000 additional compounds. In addition, the collaboration has already yielded the discovery and validation of a panel of 5 lead corrector compounds with nanomolar potency and 10-20 fold greater potency that any existing corrector drugs.

Medicinal chemistry derivatives are currently being synthesized from the most potent lead compound from a family of drugs that had common molecular structure. Patent protection is in its final stages with work being facilitated by the UAB Research Foundation. DBM and UAB investigators have mutual rights to existing and future lead compounds going forward and have contributed equally to the partnership.

"We are extremely pleased to be working with DiscoveryBioMed. Their exceptional technology and excellent small molecule screening library make them an ideal partner for this program, said James F. Collawn, Ph.D., Professor of Cell Biology at UAB. "We look forward to a continued and active scientific collaboration with DiscoveryBioMed." Dr. Collawn continued, "The SBIR grant announced today is a meaningful endorsement of our efforts investigating novel approaches to the development of therapies for the treatment of patients with CF. We believe the human airway epithelial cell model, which was acquired and licensed by DiscoveryBioMed, expressing the mutant CFTR from an endogenous gene is currently the best model for studies of this type. The funds made available through the SBIR grant will allow us to explore new ideas regarding mutant CFTR rescue and may lead to treatment alternatives for CF patients in the near future."

The grant announced today is the second to be awarded to DBM this year. The previous award, announced in September, was a Phase 2 SBIR grant to continue research into the discovery and development of small molecules to alleviate multiple chronic human diseases. About DiscoveryBioMed, Inc. DiscoveryBioMed, Inc. is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and cell-based drug discovery. T

he company is located within Innovation Depot in Birmingham. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, it focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its "fee-for-service" support to researchers in allied areas and currently serves clients both locally in Alabama as well as in 11 other states in the US currently. For more information, visit the DBM website at www.discoverybiomed.com. Discovery BioMed, Inc. Erik Schwiebert, Ph.D., 205-307-6535 x 1 erik@discoverybiomed.com or Red Mountain Communications Jonathan M. Nugent, 205-566-3026 jnugent@redmtncom.com Copyright Business Wire 2009

Copyright Business Wire 2009